健康元：公司目前已布局超过20款1类创新药

Core Viewpoint - The company has developed over 20 first-class innovative drugs, with more than 10 entering critical research phases such as Phase II and beyond [1] Group 1: Drug Development - The company has established a systematic innovative drug layout for COPD treatment, creating three targeted solutions [1] - These solutions include a targeted PDE4 inhalation formulation, a globally pioneering oral PREP inhibitor, and a new generation ICS inhalation formulation [1] Group 2: Collaborations - The company has officially launched a new polymyxin project in collaboration with Tengsheng Bo Pharmaceutical [1]